Turnstone, which went public via an $80 million IPO in 2023, ended September 2024 with $45.3 million to hand, which the ...

Turnstone Biologics shares faced a setback after Piper Sandler downgraded the company's stock rating from Overweight to Neutral. This decision was accompanied by a significant reduction in the price ...

Piper Sandler analyst Joseph Catanzaro downgraded Turnstone Biologics (TSBX) to Neutral from Overweight with a price target of 40c, down from ...

SAN DIEGO - Turnstone Biologics Corp. (NASDAQ:TSBX), a clinical-stage biotechnology company with a market capitalization of $9.45 million, has announced the discontinuation of its TIDAL-01 clinical ...

Turnstone Biologics (TSBX) has completed an assessment of its business and operations, including the status of its program, resources, and ...

San Diego, USA-based Turnstone Biologics yesterday announced that it has completed an assessment of its business and ...

Turnstone Biologics Corp’s profitability metrics reveal financial health. The company currently boasts a gross margin of -80.89%. The profit margin, also known as the revenue ratio or gross profit ...